Children's Health Defense By
An inherent defect in the modified RNA (modRNA) instructions for the spike protein in COVID-19 immunizations causes cells to produce “off-target” proteins in addition to the spike. These proteins, which developers either failed to look for or did not report to regulators, cause undesirable immune responses whose long-term effects are unknown.
Developers of the Pfizer/BioNTech BNT162b2 gene therapy immunization product (“vaccine”) overlooked or failed to anticipate a common mistake in the translation of synthetic messenger RNA (mRNA) to protein.
This mistranslation may cause the expression of potentially harmful protein side products. As a result, some people who receive the shots develop immune responses to those protein products — and scientists don’t know what, if any, long-term consequences may ensue.
The paper reporting this effect appeared in Nature in December 2023, three years after the mRNA-based vaccine rollouts and the potential to address these potentially dangerous effects had passed — but not before more than 600 million doses of the mRNA vaccines had been administered in the U.S.
Researchers including first author Thomas Mulroney, Ph.D., a Cambridge University toxicologist, found that N1-methylpseudouridine (NMpU), an artificial instruction inserted into mRNA and other mRNA-based gene therapy products, causes the machinery that translates the gene to the spike protein to “slip” about 10% of the time.
Slips, termed “frameshifts,” cause cells to skip an instruction and generate random, nonsense proteins leading to undefined, unintended immune responses.
Independent researcher David Wiseman, Ph.D., who published a critique of the Mulroney paper, told The Defender:
“We don’t know what these proteins are or their toxicities, yet there was no sense of urgency in making this discovery known. While peer review can take months for papers to be published, given the implications of these findings, ten months after receiving a manuscript is an awfully long time. Publication should have been expedited, regulatory authorities notified and actions taken.”
The immunogenicity of protein contaminants is a serious issue in biotech-made medicines, particularly for injected or infused products. For example, manufacturers devote considerable resources to eliminating host cell proteins due to their potential to cause dangerous and unpredictable immune reactions in patients.
Host cell proteins and their breakdown products are impurities originating from cells or organisms used to manufacture protein products, but they do not belong in the product. Some have been characterized but many, like frame-shifted proteins, are not…
READ FULL ARTICLE HERE…. (childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
